Scientific Reports (Oct 2023)

Routine perioperative blood tests predict survival of resectable lung cancer

  • Daniele Morelli,
  • Anna Cantarutti,
  • Camilla Valsecchi,
  • Federica Sabia,
  • Luigi Rolli,
  • Giovanni Leuzzi,
  • Giorgio Bogani,
  • Ugo Pastorino

DOI
https://doi.org/10.1038/s41598-023-44308-y
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Abstract There is growing evidence that inflammatory, immunologic, and metabolic status is associated with cancer patients survival. Here, we built a simple algorithm to predict lung cancer outcome. Perioperative routine blood tests (RBT) of a cohort of patients with resectable primary lung cancer (LC) were analysed. Inflammatory, immunologic, and metabolic profiles were used to create a single algorithm (RBT index) predicting LC survival. A concurrent cohort of patients with resectable lung metastases (LM) was used to validate the RBT index. Charts of 2088 consecutive LC and 1129 LM patients undergoing lung resection were evaluated. Among RBT parameters, C-reactive protein (CRP), lymphocytes, neutrophils, hemoglobin, albumin and glycemia independently correlated with survival, and were used to build the RBT index. Patients with a high RBT index had a higher 5-year mortality than low RBT patients (adjusted HR 1.93, 95% CI 1.62–2.31). High RBT patients also showed a fourfold higher risk of 30-day postoperative mortality (2.3% vs. 0.5%, p 0.0019). The LM analysis validated the results of the LC cohort. We developed a simple and easily available multifunctional tool predicting short-term and long-term survival of curatively resected LC and LM. Prospective external validation of RBT index is warranted.